US2020085835A1PendingUtilityA1

Novel Formulation of Meloxicam

71
Assignee: ICEUTICA PTY LTDPriority: Jun 9, 2014Filed: Nov 19, 2019Published: Mar 19, 2020
Est. expiryJun 9, 2034(~7.9 yrs left)· nominal 20-yr term from priority
A61P 25/04A61P 29/00Y10T428/2982A61K 9/1617A61K 9/0053A61K 31/00A61K 9/14A61K 9/4858A61P 19/02A61K 9/1652A61K 9/1623A61K 31/5415A61K 9/145
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam.

Claims

exact text as granted — not AI-modified
1 . A unit dosage form of a pharmaceutical composition comprising 5 mg of meloxicam, wherein a single dose, upon oral administration to a population of healthy adults in the fasted state, provides a mean plasma AUC (0-∞) of 7500-20000 h*ng/ml. 
     
     
         2 .- 12 . (canceled) 
     
     
         13 . A unit dosage form comprising 10 mg of meloxicam, wherein a single dose, upon oral administration to a population of healthy adults in the fasted state, provides a mean plasma AUC (0-∞) of 16000-44000 h*ng/ml. 
     
     
         14 .- 30 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.